Ankylosing spondylitis, late osteoarthritis, vascular calcification, chondrocalcinosis and pseudo gout: Toward a possible drug therapy

Current Medicinal Chemistry

Volumn 18, Issue 14, 2011, Pages 2196-2203

  Mebarek, S ^a,b,c,d   Hamade, E ^e   Thouverey, C ^f   Bandorowicz Pikula, J ^g   Pikula, S ^g   Magne, D ^a,b,c,d   Buchet, R ^a,b,c,d  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITÉ DE LYON   (France)

^d CPE LYON   (France)

^e LEBANESE UNIVERSITY   (Lebanon)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

Alkaline phosphatase; Ankylosing spondylitis; Calcification; Chondrocalcinosis; Hydroxyapatite; Matrix vesicle; Osteoarthritis, phosphate; Pseudo gout; Pyrophosphate; Vascular calcification

Indexed keywords

ADALIMUMAB; ALKALINE PHOSPHATASE; ANTIINFLAMMATORY AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM PYROPHOSPHATE; CHONDROITIN; COLCHICINE; ETANERCEPT; GLUCOCORTICOID; GLUCOSAMINE; HYDROXYAPATITE; INFLIXIMAB; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PLACEBO; PROTEIN ANK; PYROPHOSPHATE; TISSUE NONSPECIFIC ALKALINE PHOSPHATASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTHROPATHY; ARTICLE; BINDING AFFINITY; BLOOD VESSEL CALCIFICATION; CHONDROCALCINOSIS; DISEASE COURSE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; GENE MUTATION; GENERALIZED ARTERY CALCIFICATION OF INFANCY; GENETIC SUSCEPTIBILITY; GOUT; HUMAN; HYDROLYSIS; MINERALIZATION; NONHUMAN; OSSIFICATION; OSTEOARTHRITIS; PATHOPHYSIOLOGY; RISK FACTOR; SPINE DISEASE; UPREGULATION;

EID: 79957939470     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711795656153     Document Type: Article

References (100)

1. Sampson, H.W.; Davis, R.W.; Dufner, D.C. Spondyloarthropathy in progressive ankylosis mice: ultrastructural features of the interverterbral disk. Acta Anat. (Basel), 1991, 141, 36-41.
2. Anderson, H.C. The role of matrix vesicles in physiological and pathological calcification. Curr. Opin. Orthopaed., 2007, 18, 428-433. (Pubitemid 47263009)
3. Ali, S.Y. Apatite crystal nodules in arthritic cartilage. Eur. J. Rheumatol. Inflam., 1978, 14, 115-119. (Pubitemid 10180764)
4. Shao, J.S.; Cai, J.; Towler, D.A. Molecular mechanisms of vascular calcification Lessons learned from the aorta. Artheriosler. Thromb. Vasc. Biol., 2006, 26, 1423-1430. (Pubitemid 44288965)
5. Magne, D.; Julien, M.; Vinatier, C.; Merhi-Soussi, F.; Weiss, P.; Guicheux, J. Cartilage formation in growth plate and arteries:from physiology to pathology. BioEssays, 2005, 27, 708-716. (Pubitemid 41153355)
6. Williams, C.J. Familial calcium pyrophosphate dihydrate deposition disease and the ANKH gene. Curr. Opin. Rheumatol., 2003, 15, 326-331. (Pubitemid 36532615)
7. Zhang, W.; Doherty, M.; Bardin, T.; Barskova, V.; Guerne, P.A.; Jansen, T.L.; Leeb, B.F.; Perez-Ruiz, F.; Pimentao, J.; Punzi, L.; Richette, P.; Sivera, F.; Uhlig, T.; Watt, I.; Pascual, E. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann. Rheum. Dis., 2011doi:10.1136/ard.2010.139105
8. Richette, P.; Bardin, T.; Doherty, M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology, 2009, 48, 711-715.
9. Rutsch, F.; Böyer, P.; Nitschke, Y.; Ruf, N.; Lorenz-Depierieux, B.; Wittkampf, T.; Weissen-Plenz, G.; Fischer, R.J.; Mughal, Z.; Gregory, J.W.; Davies, J.H.; Loirat, C.; Strom, T.M.; Schnabel, D.; Nürberg, P.; Terkeltaub, R. Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ. Cardiovasc. Genet., 2008, 1, 133-140.
10. Sun, Y.; Hanley, E.N. Calcium-containing crystals and osteoarthritis. Curr. Opin. Rheumatol., 2007, 18, 472-478. (Pubitemid 47263016)
11. McCarthy, G.M.; Cheung, H.S. Point: hydroxyapatite crystal deposition is intimately involved in the pathogenesis and progression of human osteoarthritis. Curr. Rheumatol. Rep., 2009, 11, 141-147.
12. Mornet, E. Hypophosphatasia. Best Pract. Res. Clin. Rheumatol., 2008, 22, 113-127. (Pubitemid 351336923)
13. Whyte, M.P. Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocrinol. Rev., 1994, 15, 439-461. (Pubitemid 24271239)
14. Sambrook, P.; Cooper, C. Osteoporosis. Lancet, 2006, 367, 2010-2018. (Pubitemid 43867702)
15. Goronzy, J.J.; Weyand, C.M. Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res. Ther., 2009, 11, 249-253.
16. Terkeltaub, R. Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res. Ther., 2009, 11, 236.
17. Richette, P.; Bardin,T. Gout. Lancet, 2010, 375, 318-328.
18. Singer, F.R. Paget disease: when to treat and when not to treat. Nat. Rev. Rheumatol., 2009, 5, 483-489.
19. Altman, R.D. Early management of osteoarthritis. Am. J. Manag. Care, 2010, 16 Suppl. Management: S41-S47.
20. Amer, M.; Bead, V.R.; Bathon, J.; Blumenthal, R.S.; Edwards, D.N. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiol. Rev., 2010, 18, 204-212.
21. Toussirot, E. Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies. Drugs Aging, 2010, 27, 523-531.
22. Chollet-Janin, A.; Finckh, A.; Dudler, J.; Guerne, P.A. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum., 2007, 56, 688-692.
23. Hayden, M.R.; Goldsmith, D.J. Semin. Dial., Sodium thiosulfate: new hope for the treatment of calciphylaxis. Semin Dial., 2010, 23, 258-262.
24. Hessle, L.; Johnson, K.A.; Anderson, H.C.; Narisawa, S.; Sali, A.; Goding, J.W.; Terkeltaub, R.; Millan, J.L.Tissue non-specific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc. Natl. Acad. Sci. USA, 2002, 99, 9445-9449. (Pubitemid 34764633)
25. Harmey, D.; Hessle, L.; Narisawa, S.; Johnson, K.A.; Terkeltaub, R.; Millan, J.L. Concerted regulation of inorganic pyrophosphate and osteopontin by Akp2, Ennp1 and Ank. Am. J. Pathol., 2004, 164, 1199-1209.
26. Gollub, E.E.; Boesze-Battaglia, K. The role of alkaline phosphatase in mineralization. Curr. Opin. Orthopaed., 2007, 18, 444-448. (Pubitemid 47263011)
27. Wang, W.; Xu, J.; Du, B.; Kirsch, T. Role of the progressive ankylosis gene (ank) in cartilage mineralization. Mol. Cell. Biol., 2005, 18, 181-186.
28. Zaka, R.; Williams, C.J. Role of the progressive ankylosis gene in cartilage mineralization. Curr. Opin. Rheumatol., 2006, 18, 181-186. (Pubitemid 43740393)
29. Ho, A.M.; Johnson, M.D.; Kingsley, D.M. Role of the mouse ank gene in control of tissue calcification and arthritis. Science, 2000, 289, 265-270. (Pubitemid 30469899)
30. Netter, P.; Bardin, T.; Bianchi, A.; Richette, P.; Loeuille, D. The ANKH gene and familial calcium pyrophosphate dihydrate deposition disease. Joint Bone Spine, 2004, 71, 365-368. (Pubitemid 39335668)
31. i and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. Bone Miner. Res., 2003, 18, 994-1004. (Pubitemid 37294935)
32. Rutsch, F.; Ruf, N.; Vaingankar, S.; Toliat, M.R.; Suk, A.; Höhne, W.; Schauer, G.; Lehman, M.; Roscioli, T.; Schnabel, D.; Epplen, J.T.; Knisely, A.; Superti-Furga, A.; McGill, J.; Filippone, M.; Sinaiko, A.R.; Valance, H.; Hinrichs, B.; Smith, W.; Ferre, M.; Terkeltaub, R.; Nürnberg, P. Mutations in ENPP1 are associated with "idiopathic" infantile arterial calcification. Nat. Genet., 2003, 34, 379-381. (Pubitemid 36935330)
33. Ruf, N.; Uhlenberg, B.; Terkeltaub, R.; Nürnberg, P.; Rutsch, F. The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI). Human Mutation, 25: 98. doi: 10.1002/humu.9297.
34. Cheng, P.-T.; Pritzker, K.P.H. Pyrophosphate, phosphate ion interaction: effects on calcium pyrophosphate and calcium hydroxyapatite crystal formation in aqueous solutions. J. Rheumatol., 1983, 10, 769-777. (Pubitemid 14176093)
35. Garimella, R.; Bi, X.; Anderson, H.C.; Camacho, N.P. Nature of phosphate substrate as a major determinant of mineral type formed in matrix vesiclemediated in vitro mineralization: an FTIR imaging study. Bone, 2006, 38, 811-817. (Pubitemid 44498591)
36. Thouverey, C.; Bechkoff, G.; Pikula, S.; Buchet, R. Inorganic pyrophosphate as a regulator of hydroxyapatite or calcium pyrophosphate dihydrate mineral deposition by matrix vesicles. Osteoarthritis Cartilage, 2009, 17, 64-72.
37. Williams, C.J. Familial calcium pyrophosphate dihydrate deposition disease and the ANKH gene. Curr. Opin. Rheumatol., 2003, 15, 326-331. (Pubitemid 36532615)
38. Jones, A.C.; Chuc, A.J.; Arie, E.A.; Green, D.J.; Doherty, M. Diseases associated with calcium pyrophosphate deposition disease. Semin. Arthritis Rheum., 1992, 22, 188-202. (Pubitemid 23007023)
39. Smilde,T.J.; Haverman, J.F.; Schipper, P.; Hermus, A.R.; van Liebergen, F.J.; Jansen, J.L.; Familial hypokalemia/hypomagnesemia and chondrocalcinosis. J. Rheumatol., 1994, 21, 1515-1519. (Pubitemid 24261539)
40. Pritzker, K.P.H. Counterpoint: hydroxyapatite crystal deposition is not intimately involved in the pathogenesis and progression of human osteoarthritis. Curr. Rheumatol. Rep., 2009, 11, 148-153.
41. Pritzker, K.P. Calcium pyrophosphate dihydrate crystal deposition and other crystal deposition disease. Curr. Opin. Rheumatol., 1994, 5, 442-447. (Pubitemid 24218416)
42. Hughes, A.E.; McGibbon, D.; Woodward, E.; Dixey, J.; Doherty, M. Localisation of a gene for chondrocalcinosis to chromosome 5p. Hum. Mol. Genet., 1995, 4, 1225-1228.
43. Andrew, L.J.; Brancolini, V.; de la Pena, L.S.; Devoto, M.; Caeiro, F.; Marchegiani, R.; Reginato, A.; Gaucher, A.; Netter, P.; Gillet, P.; Loeuille, D.; Prockop, D.J.; Carr, A.; Wordsworth, B.F.; Lathrop, M.; Butcher, S.; Considine, E.; Everts, K.; Nicod, A.; Walsh, S.; William, C.J. Refinement of the chromosome 5p locus for familial calcium pyrophosphate dihydrate deposition disease. Am. J. Hum. Genet., 1999, 64, 136-145. (Pubitemid 30428966)
44. Ho, A.; Johnson, M.; Kingsley, D.M. Role of the mouse ank gene in tissue calcification and arthritis. Science, 2000, 289, 265-270. (Pubitemid 30469899)
45. Doherty, M. Calcium pyrophosphate dehydrate crystal-associated arthropathy. In Rheumatology. Hochberg M. Ed.; Mosby: Edimburg, 2003; pp 1937-1950.
46. Pasquetti, P.; Selvi, E.; Righeschi, K.; Fabbroni, M.; De Stefano, R.; Frati, E.; Marcolongo, R. Joint lavage and pseudogout. Ann. Rheum. Dis., 2004, 63, 1529-1530. (Pubitemid 39433972)
47. Wending, D.; Tisserand, G.; Griffond,V.; Saccomani, C.; Toussirot, E. Accute pseudogout after pamidronate infusion. Clin. Rheumatol., 2008, 27, 12005-12060.
48. Ames, P.R.; Rainey, M.G. Consecutive pseudogout attacks after repetitive granulocyte colony-stimulating factor administration for neutrpenia. Mod. Rheumatol., 2007, 17, 445-446. (Pubitemid 47593498)
49. Tam, L.S.; Gu, J.; Yu, D. Pathogenesis of ankylosing spondylitis. Nat. Rev. Rheumatol., 2010, 6, 399-405.
50. Pradeep, D.J ; Keat, A.; Gaffney, K. Predicting outcome in ankylosing spondylitis. Rheumatology, 2008, 47, 942-945. (Pubitemid 351865912)
51. Colbert, R.A.; DeLay, M.L.; Klenk, E.I. From HLA-B27 to spondyloarthritis: a journey through the ER. Immunol. Rev., 2010, 233, 181-202.
52. Brown MA. Genetics and the pathogenesis of ankylosing spondylitis. Curr. Opin. Rheumatol., 2009, 21, 318-323.
53. Tsui, H.W.; Inman, R.D.; Paterson, A.D.; Reveille, J.D.; Tsui, F.W. ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Res. Ther., 2005, 7, R13-R25.
54. Timms, A.E.; Zhang, Y.; Bradbury, L.; Wordsworth, B.P.; Brown, M.A. Investigation of the role of ANKH variants associated with ankylosing spondylitis. Arthritis Rheum., 2003, 48, 2898-2902. (Pubitemid 37280619)
55. Tsui, H.W.; Inman, R.D.; Reveille, J.D.; Tsui, F.W. Association of a TNAP haplotype with ankylosing spondylitis. Arthritis Rheum., 2007, 56, 234-243. (Pubitemid 46106197)
56. Kalya, S.; Rosental, A.K. Extracellular matrix changes regulate calcium crystal formation in articular cartilage. Curr. Opin. Rheumatol., 2005, 17, 325-329. (Pubitemid 40616580)
57. Brown MA. Genetics and the pathogenesis of ankylosing spondylitis. Curr. Opin. Rheumatol., 2009, 21, 318-323.
58. McCarthy, G.M.; Cheung, H.S. Point: hydroxyapatite crystal deposition is intimately involved in the pathogenesis and progression of human osteoarthritis. Curr. Rheumatol. Rep., 2009, 11, 141-147.
59. Ea, H.K.; Lioté, F. Advances in understanding calcium-containing crystal disease. Curr. Opin. Rheumatol., 2009, 21, 150-157.
60. Fuerst, M.; Bertrand, J.; Lammers, L.; Dreier, R.; Echtermeyer, F.; Nitschke, Y.; Rutsch, F.; Schäfer, F.K.W.; Niggemeyer, O.; Steinhagen, J.; Lohmann, C.H.; Pap, T.; Rüther, W. Calcification of articular cartilage in human osteoarthrits. Arthritis Rheum., 2009, 60, 2694-2703.
61. Ea, H.-K.; Nguyen, C.; Bazin, D.; Bianchi, A.; Guicheux, J.; Reboul, P.; Daudon, M.; Loté, F. Articular cartilage calcification in ostearthritis. Insights into crystal-induced stress. Arthritis Rheum., 2010, 63, 10-18.
62. Mitsuyama, H.; Healey, R.M.; Terkeltaub, R.A.; Coutts, R.D.; Amiel, D. Calcification of human articular knee cartilage is primarily an effect of aging rather than osteoarthritis. Osteoarthritis Cartilage, 2007, 15, 559-565. (Pubitemid 46667717)
63. Neogi, T.; Nevitt M, Niu, J.; LaValley, M.P.; Hunter, D.J.; Terkeltaub, R.; Carbone, L.; Chen, H.; Harris, T.; Kwoh, K.; Guermazi, A.; Felson, D.T. Lack of association between chondrocalcinosis and increased risk of cartilage loss in knees with osteoarthritis: results of two prospective longitudinal magnetic resonance imaging studies. Arthritis Rheum., 2006, 54, 1822-1828. (Pubitemid 43880339)
64. Kirsch, T. Determinants of pathological mineralization. Curr. Opin. Rheumatol., 2006, 18, 174-180. (Pubitemid 43740392)
65. Shao, J.S.; Cheng, S.L.; Sadhu, J.; Towler, D.A. Inflammation and the osteogenic regulation of vascular calcification. A review and perspective. Hypertension, 2010, 55, 579-592.
66. Tanimura, A.; McGregor, D.H.; Anderson, H.C. Calcification in atherosclerosis I. Human studies. J. Exp. Pathol., 1986, 2, 261-273.
67. Tanimura, A.; McGregor, D.H.; Anderson, H.C. Matrix vesicles in atherosclerotic calcification. Proc. Soc. Exp. Biol. Med., 1983, 172, 173-177. (Pubitemid 13143185)
68. Reynollds, J.L.; Joannides, A.J.; Skepper, J.N.; McNair, R.; Schurgers, L.J.; Proudfoot, D.; Jahnen-Dechent, W.; Weissberg, P.L.; Shanaham, C.M. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J. Am. Soc. Nephrol., 2004, 15, 2857-2867. (Pubitemid 41103395)
69. Kramsch, D.M.; Aspen, A.J.; Rozler, L.J. Atherosclerosis; Prevention by agents not affecting abnormal levels of blood lipids. Science, 1981, 213, 1511-1512. (Pubitemid 11031236)
70. Hashiba, H.; Aizawa, S.; Tamura, K.; Shigematsu, T.; Kogo, H. Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. Ther. Apher. Dial., 2004, 8, 241-247. (Pubitemid 38900431)
71. Van de Lest, C.H.A.; Vaandrager, A.B. Mechanism of cell-mediated mineralization. Curr. Opin. Orthopaed., 2007, 18, 434-443. (Pubitemid 47263010)
72. Shroff, R.C.; Shanahan, C.M. The vascular biology of calcification. Seminars in Dialysis, 2007, 20, 103-109.
73. Hsu, H.H.; Camacho, N.P. Isolation of calcifiable vesicles from human atherosclerotic aortas. Atherosclerosis, 1999, 143, 353-362. (Pubitemid 29166916)
74. Luo, G.; Ducy, P; McKee, M.D.; Pinero, G.J.; Loyer, E.; Behringer, R.R.; Karsenty, G. Spontaneous calcification of arteries and cartilage in matrix lacking GLA protein. Nature, 1997, 386, 78-81. (Pubitemid 27130923)
75. Mumroe, P.B.; Olgunturk, R.O.; Fryns, J.P.; Van Maldergem, L.; Ziereisen, F.; Yuksel, B.; Gardiner, R.M.; Chung, E. Mutations in gene encoding the human Gla protein cause Keutel syndrome. Nat. Genet., 1999, 21, 142-144. (Pubitemid 29036302)
76. Galvin, K.M.; Donovan, M.J.; Lynch, C.A.; Meyer, R.I.; Paul, R.J.; Lorenz, J.N.; Fairchild-Huntress, V.; Dixon, K.L.; Dunmore, J.H.; Gimbrone, M.A.Jr.; Falb, D.; Huszar, D. A role for smad6 in development and homeostasis of the cardiovascular system. Nat. Genet., 2000, 24, 171-174. (Pubitemid 30094719)
77. Schafer, C.; Heiss, A.; Schwarz, A.; Westenfeld, R.; Ketteler, M.; Floege,J.; Muller-Esterl, W.; Schinke, T.; Jahnen-Dechent, W. The serum protein alpha-2 Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J. Clin. Invest., 2003, 112, 357-366. (Pubitemid 38063764)
78. Bucay, N.; Sarosi, I.; Duncan, C.R.; Morony, S.; Tarpley, J.; Capparelli, C.; Scully, S.; Tan, H.L.; Xu, W.; Lacey, D.L.; Boyle, W.J.; Simonet, W.S. Osteoplrotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev.; 1998, 12, 1260-1268. (Pubitemid 28213402)
79. Nabeshima, Y. Ectopic calcification in Klotho mice. Clin. Calcium, 2003, 12, 114-1117.
80. Van der Heijde, D.; Dijkmans, B.; Geusens, P.; Sieper, J.; DeWoody, K.; Williamson, P.; Braun, J. Efficacy and safety of infliximab in patients with ankylosing spondylitis - Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum., 2005, 52, 582-591. (Pubitemid 40216323)
81. Antoni, C.; Krueger, G. G.; de Vlam, K.; Birbara, C.; Beutler, A.; Guzzo, C.;Zhou, B.; Dooley, L.T.; Kavanaugh, A. Ann. Rheum. Dis., 2005, 64, 1150-1157.
82. Brandt, J.; Khariouzov, A.; Listing, J.; Haibel, H.; Sörensen, H.; Grassnickel, L.; Rudwaleit, M.; Sieper, J.; Braun, J. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum., 2003, 48, 1667-1675. (Pubitemid 36682375)
83. Van der Heijde, D.; Kivitz, A.; Schiff, M. H.; Sieper, J.; Dijkmans, B. A.; Braun, J.; Dougados, M.; Reveille, J. D.; Wong, R. L.; Kupper, H.; Davis, J. C. Jr. Efficacy and safety of adalimumab in patients with ankylosing spondylitis - Results of a multicenter, randomized, double-blind, placebocontrolled trial. Arthritis Rheum., 2006, 54, 2136-2146. (Pubitemid 44051069)
84. Stinghen, A. M. S.; Bucharles, S.; Riella, M. C.; Pecoits-Filho, R. Immune Mechanisms Involved in Cardiovascular Complications of Chronic Kidney Disease. Blood Purif., 2010, 29, 114-120.
85. Crosby, J. Osteoarthritis: Managing without surgery. J. Fam. Pract., 2009, 58, 354-361.
86. Guerne, P.A. Chondrocalcinosis and calcium pyrophosphate (CPP) crystal deposition disease in 2010. Rev. Med. Suisse, 2010, 6, 555-6, 558, 560-1.
87. Lioté, F.; Ea H.K. Recent developments in crystal-induced inflammation pathogenesis and management. Cur. Rheumatol. Rep., 2007, 9, 243-250. (Pubitemid 46954784)
88. Pascual, E. Management of crystal arthritis. Rheumatology (Oxford), 1999, 38, 912-6. (Pubitemid 29505071)
89. Cundy, T.; Bolland, M. Paget disesease of bone. Trends Endocinol. Metab., 2008, 19, 246-253.
90. Krsnokutsky, S.; Samuels, J.; Abramson,S.B. Osteoarthritis in 2007. Bulletin of NYU Hospital for Joint diseases, 2007, 65, 222-228. (Pubitemid 351412136)
91. Saig, K.G. Biphosphonates for osteoarthritis prevention:"Holy Grail or not?". Ann. Rheum. Dis., 2008, 67, 1358-1359.
92. Elmariah, S.; Delaney, J.A.C.; O'Brien, K.D.; Budoff, M.J.;Vogel- Claussen,J.; Fuster, V.; Kronmal, R.A.; Halperin, J.L. Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women. J. Am. CollegeCardiol., 2010, 56, 1753-1759.
93. Altman, R.D. Pharmacological therapies for osteoarthritis of the hand: a review of the evidence. Drugs Aging, 2010, 9, 729-745.
94. Wandel, S.; Jüni, P.; Tendal, B.; Nüesch, E.; Villiger, P.M.; Welton, N.J.; Reichenbach,S.; Trelle, S. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010 341:c4675. doi: 10.1136/bm
95. Chevalier, X. Intraarticular treatment for osteoarthritis: New Perspectives. Curr. Drug Targets, 2010, 11, 546-560.
96. Li, L.; Chang, L.; Pellet-Rostaing, S.; Liger, F.; Lemaire, M.; Buchet, R.; Wu, Y. Synthesis and evaluation of benzo[b]thiophen derivatives as inhibitors of alkaline phosphatases. Bioorg. Med. Biochem., 2009, 17, 7290-7300.
97. Sallis, J.D.; S. Cheung,H.S. Inhibitors of articular calcium crystal formation. Curr. Opin. Rheumatol., 2003, 15, 321-325 (Pubitemid 36532614)
98. Narisawa, S.; Harmey, D.; Yadav, M.C.; O'Neil, W.C.; Hoylaerts, M.F.; Millan, J.L. Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J. Bone Min. Res., 2007, 22, 1700-1710. (Pubitemid 351235136)
99. Lomashvili, K.A.; Garg, P.; Narisawa, S.; Millan, J.L.; O'Neil, W.C. Upregalation of alkaline phosphatasae and pyrophosphatase hydrolysis: Potential mechanism for uremic vascular calcification. Kidney Int., 2008, 73, 1024-1030. (Pubitemid 351543906)
100. Dahl, R.; Sergienko, E.A.; Su,Y.; Mostofi, Y.S.; Yang, L.; Simao, A.M.; Narisawa, S.; Brown, B.; Mangravita-Novo, A.; Vicchiarelli, M.; Smith, L.H.; O'Neil, W.C.; Millan, J.L.; Cosford, N.D.P. Discovery and validation of a series of aryl sulfonamides as selective inhibitors of tissue-nonspecific alkaline phosphatase (TNAP). J. Med. Chem., 2009, 52, 6919-6925.